Vertex aims at not only new patients, but on keeping those they have

On Wednesday evening, Vertex Pharmaceuticals for the first time gave its own estimates on sales of its newly launched drug for cystic fibrosis, Orkambi. And with that, it gave a detailed analysis that underscored how important it is not only for the company to attract new patients, but to make sure those patients take their pills as prescribed, and that as few of them as possible stop. The sales estimate itself came in at between $1 billion and $1.1 billion by the end of 2016, which was on the low…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news